ALSO NOTED: Celera moves to cut staff; FDA expands Emend use; FDA approves Perrigo gel; and much more...

> A restructuring at Celera Genomics will include laying off 180 staffers. Report [1]

> The FDA has expanded its approval for Merck's nausea drug Emend to include cancer patients undergoing chemotherapy. Report [2]

> Perrigo's stock ticked up on news that the FDA had approved its desoximetasone gel for skin conditions. Report [3]

> AmpliMed has won European approval for orphan drug status for its lead drug, Amplimexon, for the treatment of ovarian cancer. Release [4]

> Cephalon and Mylan have signed two new collaborations to develop transdermal products for pain and CNS disorders. Report [5]

> PR Pharmaceuticals has struck a deal with OSI Pharmaceuticals to collaborate on the development of a sustained release formulation of Macugen. Release [6]

> ProMetic Life Sciences of Canada has raised $8.9 million in financing. Release [7]

> Threshold Pharmaceuticals has announced positive results from the Phase 1 portion of a Phase 1/2 dose-escalation study of glufosfamide in combination with gemcitabine for the treatment of advanced solid tumors and pancreatic cancer. Release [8]

And Finally… Seven years after New York health officials initiated an ambitious effort to control diabetes, much of the effort has shut down as disease rates have doubled. Insurers are getting the blame; their policies will quickly reimburse for expensive treatments but neglect crucial preventive care. Article [9]